283
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant

, , , , , , , , & show all
Pages 973-978 | Received 02 Feb 2012, Accepted 22 Sep 2012, Published online: 29 Oct 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Rajshekhar Chakraborty, Shiva Kumar Reddy Mukkamalla, Garfield Gutzmore & Hon Cheung Chan. (2015) A case of Hodgkin’s lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD. Journal of Blood Medicine 6, pages 93-97.
Read now
Vijayveer Bonthapally, Hongbo Yang, Rajeev Ayyagari, Ruo-Ding Tan, Sean Cai, Eric Wu, Ashish Gautam, Andy Chi & Dirk Huebner. (2015) Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis. Current Medical Research and Opinion 31:7, pages 1377-1389.
Read now

Articles from other publishers (3)

Panagiotis Tsirigotis, Theodoros Vassilakopoulos, Ioannis Batsis, Zoi Bousiou, Konstantinos Gkirkas, Ioanna Sakellari, Panayotis Kaloyannidis, Paraskevi Roussou, Gerassimos A. Pangalis, Maria Moschogiannis, George Vassilopoulos, Panagiotis Repousis, Aekaterini Megalakaki, Eurydiki Michalis, Christina Kalpadakis, Helen A. Papadaki, Ioannis Kotsianidis, Eleftheria Hatzimichael, Alexandros Spyridonidis, Konstantinos Anargyrou, Elias Poulakidas, Panagiota Giannoullia, Ioannis Apostolidis, Maria Stamouli, Konstantinos Konstantopoulos, Vassiliki Pappa, Panayiotis Panayiotidis, Nikolaos Harhalakis, Achilles Anagnostopoulos & Maria Angelopoulou. (2018) Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. Hematological Oncology 36:4, pages 645-650.
Crossref
C.Y. Cheah, D. Chihara, S. Horowitz, A. Sevin, Y. Oki, S. Zhou, N.H. Fowler, J.E. Romaguera, F. Turturro, F.B. Hagemeister, L.E. Fayad, M. Wang, S.S. Neelapu, L.J. Nastoupil, J.R. Westin, M.A. Rodriguez, F. Samaniego, P. Anderlini, Y. Nieto & M.A. Fanale. (2016) Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology 27:7, pages 1317-1323.
Crossref
Eliza A. Hawkes, Sarah Barton, David Cunningham, Clare Peckitt, Sue Chua, Andrew Wotherspoon, Alan Horwich, Mike Potter, Mark Ethel, Claire Dearden & Ian Chau. (2013) GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. Annals of Hematology 93:5, pages 827-834.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.